Yhhu-3792 is a novel small molecule that enhances the self-renewal capability of neural stem cells (NSCs) in vitro and in vivo via activating the Notch signaling pathway; activates Notch signaling pathway and promotes the expression of Notch target genes, Hes3 and Hes5; expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) after chronic administration in mice.
1,6,11-Trimethyl-1,2-dihydrofuro[2',3':1,2]phenanthro[4,3-d]oxazole (compound 1) is a potent anti-HIV-1 agent[1].
23-O-Demycinosyltylosin (23-DMT; 23-Demycinosyltylosin) is a 23-O-demycinosyltylosin (DMT) acyl derivative with antibacterial activity[1].
BTS is a potent inhibitor of Ca2+-stimulated myosin S1 ATPase (IC50 ~ 5 μM) and reversibly blocks the gliding motility. IC50 value: 5 uMTarget: Ca2+-stimulated myosin S1 ATPaseBTS also weakens myosin’s interaction with F-actin. BTS is much less effective in suppressing contraction in rat myocardial or rabbit slow twitch muscle and has no effect on platelet myosin II.
OTS186935 trihydrochloride is a protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS186935 trihydrochloride regulates the production of γ-H2AX in cancer cells[1].
Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.Target: NRTIs; HBVAdefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil is used for treatment of hepatitis B and herpes simplex virus infection [1-3]. Adefovir Dipivoxil is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease. Adefovir Dipivoxil is a failed treatment for HIV[3, 4].
Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research[1].
CGP 20712 dihydrochloride is an antagonist of β 3-adrenoceptor. CGP 20712 dihydrochloride inhibits isoproterenol with the IC50 of 79 μM[1].
PRMT1-IN-1 is a PRMT1 inhibitor.
Naloxone D5 is deuterium labeled Naloxone. Naloxone is a a potent opioid receptor antagonist.
Fmoc-N-Me-Leu-OH, an N-Fmoc-N-methyl amino acid, is available for the peptide-coupling reaction.
Dexamethasone acetate is a glucocorticoid receptor agonist.
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities[1][2]
(R)-ND-336 is a potent and selective MMP-9 inhibitor with a Ki of 19 nM. (R)-ND-336 inhibits MMP-2 (Ki=127 nM) and MMP-14 (Ki=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research[1].
6-O-Methyl Guanosine is a modified nucleoside[1]. 6-O-Methyl Guanosine (6-methylguanosine) inhibit colony-forming ability in a malignant xeroderma pigmentosum cell line[2].
PACAP (6-38), human, ovine, rat is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.
SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity[1][2].
PrDiAzK is a bifunctional amino acid. PrDiAzK can be site-selectively incorporated into proteins in both bacterial and mammalian cell culture. PrDiAzK can be used for proteome-wide incorporation via stochastic orthogonal recoding of translation (SORT)[1].
FL-411 is a potent and selective BRD4 inhibitor with an IC50 of 0.43±0.09 μM for BRD4(1).
Piperundecalidine is an amide alkaloids that can be purified from Piper longum L. Piperundecalidine shows various biological properties, such as anti-inammatory, analgesic, anti-amoebic, anti-depressant, hepatoprotective,etc.[1].
Keap1-Nrf2-IN-12 is a potent Keap1-Nrf2 inhibitor with an IC50 value of 2.30 µM. Keap1-Nrf2-IN-12 shows metabolic stability in human liver microsomes[1].
TUG-891 is a potent and selective agonist of the long chain free fatty acid (LCFA) receptor 4.
BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1].
Tanshindiol B, a naphthaquinone diterpene, inhibits GBM growth by induction of noptosis (NQO1-dependent necrosis)[1].
Lacto-N-neodifucohexaose II (Compd 9) is a derivative of key human milk tetrasaccharide[1].
OXA(17-33) is a potent and selective orexin-1 receptor (OX1) agonist. OXA(17-33) shows a ∼23-fold selectivity for the OX1 (EC50=8.29 nM) over OX2 (187 nM)[1].
Metoclopramide-d3 is deuterium labeled Metoclopramide. Metoclopramide is a potent antagonist of 5-HT3 and dopamine D2 receptor, with IC50s of 308 nM and 483 nM, respectively. Metoclopramide can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis[1][2].
DDR1-IN-3 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM.
Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.IC50 value:Target: Aβ-ABAD interaction